Hyperkalemia associated with spironolactone therapy.
作者信息
Dolovich Lisa, Gavura Scott, Pottie Kevin
机构信息
Centre for Evaluation of Medicines, St Joseph's Healthcare in Hamilton, Ontario.
出版信息
Can Fam Physician. 2005 Mar;51(3):357-60.
Abstract
摘要
相似文献
1
Hyperkalemia associated with spironolactone therapy.
Can Fam Physician. 2005 Mar;51(3):357-60.
2
Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
Pharmacoepidemiol Drug Saf. 2015 Apr;24(4):406-13. doi: 10.1002/pds.3748. Epub 2015 Feb 12.
3
Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Kobe J Med Sci. 2005;51(1-2):1-6.
4
Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.
JAMA Dermatol. 2015 Sep;151(9):941-4. doi: 10.1001/jamadermatol.2015.34.
5
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med. 2004 Aug 5;351(6):543-51. doi: 10.1056/NEJMoa040135.
6
The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
J Am Coll Cardiol. 2005 Sep 6;46(5):845-9. doi: 10.1016/j.jacc.2005.06.010.
7
Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
J Coll Physicians Surg Pak. 2003 Jul;13(7):382-4.
8
Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Am J Cardiol. 2012 Mar 1;109(5):693-8. doi: 10.1016/j.amjcard.2011.10.027. Epub 2011 Dec 5.
9
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Circ Heart Fail. 2014 Jul;7(4):573-9. doi: 10.1161/CIRCHEARTFAILURE.114.001104. Epub 2014 May 8.
10
Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
J Clin Pharm Ther. 2005 Dec;30(6):603-10. doi: 10.1111/j.1365-2710.2005.00694.x.
引用本文的文献
1
Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
Mayo Clin Proc. 2020 Nov;95(11):2408-2419. doi: 10.1016/j.mayocp.2020.03.035.
2
Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer.
ESC Heart Fail. 2020 Oct;7(5):3161-3164. doi: 10.1002/ehf2.12711. Epub 2020 Jun 17.
3
Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.
Ann Card Anaesth. 2019 Apr-Jun;22(2):162-168. doi: 10.4103/aca.ACA_65_18.
4
Aldosterone antagonists in systolic heart failure.
Can Fam Physician. 2014 Feb;60(2):e104.
本文引用的文献
1
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.
N Engl J Med. 2004 Aug 5;351(6):585-92. doi: 10.1056/NEJMra035279.
2
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).
J Am Coll Cardiol. 2001 Dec;38(7):2101-13. doi: 10.1016/s0735-1097(01)01683-7.
3
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001.
Zotero 插件